Antiviral Drugs Market to Foresee Tremendous Gains Over 2020-2026
The global antiviral drugs market was valued at $56 billion in 2019 and is expected to accrue phenomenal gains over the forecast period. The spread of covid-19 pandemic has gradually started to affect the antiviral drugs market in 2020 and has boosted the demand for these drugs globally. Moreover, the new crown epidemic is likely to raise substantial awareness for antiviral drugs.
Antiviral drugs market is segmented into type and application spectrum. In terms of type segmentation, the industry is bifurcated into fusion inhibitors, immune system modulators, protease inhibitors, and reverse transcriptase inhibitors.
The application spectrum includes HIV/AIDS therapeutics, hepatitis therapeutics, herpes therapeutics, and influenza therapeutics. The market analysis offers an in-dept knowledge on the industrial trends across various regions like Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. Amongst these, China has established its place in the antiviral drugs market procuring a significant share of the overall industry. In addition to this, the report also provides an insight into the impact of global and local market players, trade regulations, value chain optimization, opportunities analysis, technological trends, product launches, and strategic market growth analysis.
The continuous penetration of coronavirus has contributed to the use of related antiviral drugs like lopinavir, ribavirin, and Interferon Alfa on the global level. Out of these, the use of ribavirin has significantly risen in the recent times.
Antiviral drugs have found abundant use in treatment of common viral diseases in humans, including, HIV/AIDS, Hepatitis, Herpes, Influenza, and several others. It was observed that, in 2019, the major applications of antiviral drugs, HIV/AIDS Therapeutics and Hepatitis accounted for more than 73% in the global industry.
Based on the application spectrum, the report states that hepatitis C remained the remunerative application for antiviral drugs before 2016 whose growth significantly subsided in a few years. Post this downfall, HIV drugs have become the prominent category to maintain overall market growth of antiviral drugs, since 2018. One of the reasons for this prolific growth of antiviral drugs is the increasing trend of influenza virus epidemics in recent years. For the treatment of influenza, the antiviral drugs majorly used include Nucleos(t)ide, Direct-acting Antiviral Agents, Interferon Alfa, and multiple others.
In terms of the product type, the worldwide antiviral drugs market is segmented into protease inhibitors, reverse transcriptase inhibitors, immune system modulators, and fusion inhibitors.
Considering the regional demographics, China has been deemed to emerge as a profitable ground for the growth of antiviral drugs industry, given the emergence and spread of covid-19 epidemic in the state. While looking out for a viable treatment for coronavirus, China began experimenting with Failover, an antiviral drug. However, seeing the constant increase in corona positive cases, the state began using other related antiviral drugs like lopinavir, ribavirin, etc, to cure the patients suffering from the epidemic.
Before the spread of novel coronavirus, these drugs were mainly used for hepatitis B treatment nationwide. Amongst these, entecavir is considered to the main treatment drug, which was apparently substituted by tenofovir and propofol owing to the stringent regulatory policies and high prices.
Global antiviral drugs market is highly concentrated and boasts the presence of prominent industry players, such as Novartis, Roche, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, Gilead Sciences, CHITAI TIANQING, Cosunter Pharmaceutical, and Qingfeng Pharmaceutical, etc.
To access a sample copy or view this report in detail along with the table of contents, please click the link below:
Worldwide antiviral drugs industry is fragmented on the basis of types, applications, regional aspects, and competitive landscape:
Antiviral Drugs Market Type Analysis (revenue, USD million, 2015-2026)
-Fusion Inhibitors
-Immune system Modulators
-Protease Inhibitors
-Reverse Transcriptase Inhibitors
Antiviral Drugs Market Application Analysis (revenue, USD million, 2015-2026)
-Hepatitis Therapeutics
-HIV/AIDS Therapeutics
-Herpes Therapeutics
-Influenza Therapeutics
Antiviral Drugs Market Regional Analysis (revenue, USD million, 2015-2026)
Asia-Pacific
-China
-Japan
-South Korea
-India
-Australia
-Taiwan
-Indonesia
-Thailand
-Malaysia
-Philippines
-Vietnam
Europe
-Germany
-France
-UK
-Italy
Russia
Latin America
-Mexico
-Brazil
-Argentina
Middle East & Africa
-Turkey
-Saudi Arabia
-UAE
North America
-US
Canada
Antiviral Drugs Market Competitive Landscape Analysis (revenue, USD million, 2015-2026)
-Novartis
-Roche
-Bristol Myers Squibb
-GlaxoSmithKline
-Johnson & Johnson
-Merck
-AbbVie
-Gilead Sciences
-CHITAI TIANQING
-Cosunter Pharmaceutical
-Qingfeng Pharmaceutical
-Others
Related Reports
Over-the-Counter (OTC) Drugs Market Share & Forecast, 2019 – 2025
Over-the-Counter (OTC) Drugs Market will reach over $185 billion by 2025; as per a new research report. Growing elderly population base, highly prone to suffer from several ailments such as joint pain will drive the demand of OTC drugs. Rising awareness about numerous diseases and accessibility of non-prescription for the same will continue to aid self-medication trend during the projection years. Across the globe, ophthalmic OTC drugs market will witness 6.0% CAGR in future because of demand arising from growing needs of elderly population vulnerable to eye related diseases.
Atrial Fibrillation Drugs Market Share & Forecast, 2019 – 2025
Atrial Fibrillation Drugs Market will exceed $17.0 billion by 2025; as per a new research report. Growing number of geriatric population and increasing prevalence of valvular diseases will boost atrial fibrillation drugs industry growth worldwide. Moreover, rising adoption rate of sedentary lifestyle coupled with increasing habit of binge eating among the millennials in developed as well as developing countries will prove to be a high impact rendering factor for the atrial fibrillation drugs market growth during forthcoming years. US atrial fibrillation drugs market will witness a growth of 2.4% during the forecast period. Increasing number of major industry players in U.S. facilitates efficient treatment option for patients with atrial fibrillation. Moreover, rising prevalence of chronic diseases such as diabetes, hypertension, etc. will further augment US atrial fibrillation market growth.
Market Study Report, LLC. is a hub for market intelligence products and services. We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place. Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company’s core activities. If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.
Market Study Report LLC
Phone: 1-302-273-0910
Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Total Page Views: 2956
